DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Type 2 inflammation
Type 2 inflammation
Use of Mepolizumab in Adult Patients with Cystic Fibrosis and An
Type 2 Immunity in Tissue Repair and Fibrosis
Download
Atopic Dermatitis: an Expanding Therapeutic Pipeline for a Complex Disease
The Role of Dupilumab in Severe Asthma
The Use of Biologics for Immune Modulation in Allergic Disease
Type 2 Inflammation in Asthma
A Review on the Effect of COVID-19 in Type 2 Asthma and Its Management
Targeting Key Proximal Drivers of Type 2 Inflammation in Disease
Understanding the Key Issues in the Treatment of Uncontrolled Persistent Asthma with Type 2 Inflammation
New Dupixent® (Dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to Be Presented at 2021 AAAAI Annual Meeting
The Regulation and Function of Thymic Stromal Lymphopoietin Receptor (TSLPR)
Efficacy and Safety of Lebrikizumab
Alternative Splicing of Interleukin-33 and Type 2 Inflammation in Asthma
IL-13 Is a Driver of COVID-19 Severity
Orchestration Between Ilc2s and Th2 Cells in Shaping Type 2 Immune Responses
Media Update
Innate and Adaptive Type 2 Immunity in Lung Allergic Inflammation
Top View
Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks
A New Perspective for Biological Therapies of Severe Asthma
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
Targeting Type 2 Inflammation for Treatment of Bullous Pemphigoid
Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia
Biologics for Type 2 Severe Asthma: What Is the Evidence?
The Regulatory Effects of Interleukin-4 Receptor Signaling on Neutrophils in Type 2 Immune Responses
Indirect Comparison of Efficacy of Dupilumab Versus Mepolizumab and Omalizumab for Severe Type 2 Asthma
Type 2 Inflammation in Atopic Dermatitis and Beyond: Shared Pathophysiology and Clinical Management
Pruritus As a Distinctive Feature of Type 2 Inflammation
Biological Therapies Targeting the Type 2 Inflammatory Pathway in Severe Asthma (Review)
IL-37 Targets TSLP-Primed Basophils to Alleviate Atopic Dermatitis
Extrafollicular Igd+ B Cells Generate Ige Antibody Secreting Cells in the Nasal Mucosa
Targeting Key Proximal Drivers of Type 2 Inflammation in Disease
Type 2 Immunity in Asthma Marco Caminati1*, Duy Le Pham2, Diego Bagnasco3 and Giorgio Walter Canonica4
Biologic Treatments for Asthma and Chronic Obstructive Pulmonary Disorder
GINA DIFFICULT-TO-TREAT & SEVERE ASTHMA in Adolescent And
The Role of the IL-33/ST2 Axis in Autoimmune Disorders Friend Or